K
Kathleen Graham
Researcher at University of Pennsylvania
Publications - 8
Citations - 717
Kathleen Graham is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Macrophage & Pancreatic cancer. The author has an hindex of 5, co-authored 7 publications receiving 443 citations.
Papers
More filters
Journal ArticleDOI
Hepatocytes direct the formation of a pro-metastatic niche in the liver
Jae W. Lee,Meredith L. Stone,Paige M. Porrett,Stacy K. Thomas,Chad A. Komar,Joey H. Li,Devora Delman,Kathleen Graham,Whitney L. Gladney,Xia Hua,Taylor A. Black,Austin L. Chien,Krishna S. Majmundar,Jeffrey C. Thompson,Stephanie S. Yee,Mark H. O'Hara,Charu Aggarwal,Dong Xin,Abraham Shaked,Mingming Gao,Dexi Liu,Mitesh J. Borad,Ramesh K. Ramanathan,Ramesh K. Ramanathan,Erica L. Carpenter,Ailing Ji,Maria C. de Beer,Frederick C. de Beer,Nancy R. Webb,Gregory L. Beatty +29 more
TL;DR: It is shown that hepatocytes coordinate myeloid cell accumulation and fibrosis within the liver and, in doing so, increase the susceptibility of the liver to metastatic seeding and outgrowth.
Journal ArticleDOI
IFNγ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma
Kristen B. Long,Whitney L. Gladney,Graham M. Tooker,Kathleen Graham,Joseph A. Fraietta,Gregory L. Beatty +5 more
TL;DR: It is reported that CD40 agonists improve chemotherapy efficacy in pancreatic carcinoma by redirecting tumor-infiltrating monocytes/macrophages to induce fibrosis degradation that is dependent on MMPs.
Journal ArticleDOI
Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47−mediated ‘don’t-eat-me’ signal
Mingen Liu,Roddy S. O’Connor,Sophie Trefely,Sophie Trefely,Kathleen Graham,Nathaniel W. Snyder,Gregory L. Beatty +6 more
TL;DR: It is shown that stimulation with a CpG oligodeoxynucleotide, a Toll-like receptor 9 agonist, evokes changes in the central carbon metabolism of macrophages that enable antitumor activity, including engulfment of CD47+ cancer cells.
Journal ArticleDOI
Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery.
TL;DR: The value of genetic mouse models for characterizing the immunobiology of PDAC and for investigating novel immunotherapeutics are considered and several variants of these models are described, which may be used in drug development and for providing information on unique aspects of disease biology and therapeutic responsiveness.
Journal ArticleDOI
A rational mouse model to detect on-target, off-tumor CAR T cell toxicity.
Mauro Castellarin,Caroline Sands,Tong Da,John Scholler,Kathleen Graham,Elizabeth L. Buza,Joseph A. Fraietta,Yangbing Zhao,Carl H. June +8 more
TL;DR: A mouse model with stable and tunable human HER2 (hHER2) expression on normal hepatic tissue and compared toxicity between affinity-tuned HER2 CAR T cells outperformed the HA-CARTs with superior antitumor efficacy in vivo highlights the importance of T cell targeting in reducing toxicity of normal tissue and also in preventing off-tumor sequestration of CARTs, which reduces their therapeutic potency.